Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials

• Published in: PloS one 2011-03, Vol.6 (3), p.e16633
• Main Authors: Ferte, Charles, Soria, Jean-Charles, Penel, Nicolas
• Format: Article
• Language: English
• Subjects: Anticancer properties; Biology; Bone cancer; Cancer therapies; Clinical trials; Clinical Trials, Phase I as Topic; Cytotoxic agents; Cytotoxicity; Dose-Response Relationship, Drug; Drug dosages; Effectiveness; Humans; Immunoglobulins; Maximum Tolerated Dose; Medical research; Medicine; Mutation; Oncology; Quantitative analysis; Signs; Studies; Task forces; Toxicity; Treatment Outcome; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0016633

Phase 1 trials play a crucial role in oncology by translating laboratory science into efficient therapies. Molecular targeted agents (MTA) differ from traditional cytotoxics in terms of both efficacy and toxicity profiles. Recent reports suggest that higher doses are not essential to produce the optimal anti-tumor effect. This study aimed to assess if MTA could achieve clinical benefit at much lower dose than traditional cytotoxics in dose seeking phase 1 trials. We reviewed 317 recent phase 1 oncology trials reported in the literature between January 1997 and January 2009. First sign of efficacy, maximum tolerated dose (MTD) and their associated dose level were recorded in each trial. Trials investigating conventional cytotoxics alone, MTA alone and combination of both represented respectively 63.0% (201/317), 23.3% (74/317) and 13.7% (42/317) of all trials. The MTD was reached in 65.9% (209/317) of all trials and was mostly observed at the fifth dose level. First sign of efficacy was less frequently observed at the first three dose-levels for MTA as compared to conventional cytotoxics or combinations regimens (48.3% versus 63.2% and 61.3%). Sign of efficacy was observed in the same proportion whatever the treatment type (73-82%). MTD was less frequently established in trials investigating MTA alone (51.3%) or combinations (42.8%) as compared to conventional cytotoxic agents (75.6%). First sign of efficacy was less frequently reported at the early dose-levels and MTD was less frequently reached in trials investigating molecular targeted therapy alone. Similar proportion of trials reported clinical benefit.